These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34179728)

  • 41. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
    Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
    J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.
    Quan FS; Kim YC; Song JM; Hwang HS; Compans RW; Prausnitz MR; Kang SM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1433-9. PubMed ID: 23863506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.
    Kim JR; Holbrook BC; Hayward SL; Blevins LK; Jorgensen MJ; Kock ND; De Paris K; D'Agostino RB; Aycock ST; Mizel SB; Parks GD; Alexander-Miller MA
    J Virol; 2015 Jul; 89(14):7291-303. PubMed ID: 25948746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
    Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
    mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine.
    Adler-Moore J; Munoz M; Kim H; Romero J; Tumpey T; Zeng H; Petro C; Ernst W; Kosina S; Jimenez G; Fujii G
    Vaccine; 2011 Jun; 29(27):4460-8. PubMed ID: 21545821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.
    Dong C; Wang Y; Gonzalez GX; Ma Y; Song Y; Wang S; Kang SM; Compans RW; Wang BZ
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin.
    Shin JH; Lee JH; Jeong SD; Noh JY; Lee HW; Song CS; Kim YC
    Drug Deliv Transl Res; 2020 Jun; 10(3):815-825. PubMed ID: 32141036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonosoff GP; Ravin NV
    BMC Biotechnol; 2015 May; 15():42. PubMed ID: 26022390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
    Quan FS; Kim MC; Lee BJ; Song JM; Compans RW; Kang SM
    Virology; 2012 Sep; 430(2):127-35. PubMed ID: 22658901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.
    Schotsaert M; Ysenbaert T; Neyt K; Ibañez LI; Bogaert P; Schepens B; Lambrecht BN; Fiers W; Saelens X
    Mucosal Immunol; 2013 Mar; 6(2):276-87. PubMed ID: 22806098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Yang WT; Yang GL; Wang Q; Huang HB; Jiang YL; Shi CW; Wang JZ; Huang KY; Jin YB; Wang CF
    Antiviral Res; 2017 Feb; 138():9-21. PubMed ID: 27908830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.
    Eliasson DG; Omokanye A; Schön K; Wenzel UA; Bernasconi V; Bemark M; Kolpe A; El Bakkouri K; Ysenbaert T; Deng L; Fiers W; Saelens X; Lycke N
    Mucosal Immunol; 2018 Jan; 11(1):273-289. PubMed ID: 28295019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
    Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
    PLoS One; 2018; 13(1):e0190868. PubMed ID: 29324805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.
    Littauer EQ; Mills LK; Brock N; Esser ES; Romanyuk A; Pulit-Penaloza JA; Vassilieva EV; Beaver JT; Antao O; Krammer F; Compans RW; Prausnitz MR; Skountzou I
    J Control Release; 2018 Apr; 276():1-16. PubMed ID: 29496540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.